# Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

> **NCT05242133** · PHASE3 · COMPLETED · sponsor: **Cinnagen** · enrollment: 168 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis (RRMS)

## Interventions

- **DRUG:** Pegylated interferon beta-1a
- **DRUG:** Interferon Beta-1A Prefilled Syringe

## Key facts

- **NCT ID:** NCT05242133
- **Lead sponsor:** Cinnagen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-20
- **Primary completion:** 2022-04-27
- **Final completion:** 2022-04-27
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2022-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05242133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05242133, "Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05242133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*